Seres Therapeutics (MCRB) revenue and earnings history
Seres Therapeutics reported revenue of $789K for fiscal 2025 (year ended Dec 31, 2025), and net income of $5.7M.
Revenue and net income, 13 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $789K | −$94M | $5.7M | $1.12M | $252K | $865K | $10.8M | — | — | $45.8M | — | 10-K |
| 2024ended Dec 31, 2024 | $0 |
The latest quarter, insider trades and fund moves: Seres Therapeutics (MCRB) on OQRO.
Common questions
What was Seres Therapeutics's revenue in fiscal 2025?
$789K for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 12, 2026.
Has Seres Therapeutics been profitable?
It reported a net loss in 11 of the years shown (2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023). The highest net income was $5.7M in fiscal 2025.
What was Seres Therapeutics's free cash flow in fiscal 2025?
$865K: operating cash flow of $1.12M minus capital expenditure of $252K. OQRO calculates free cash flow this way from the two filed lines.
Where these figures come from
The SEC’s companyfacts data: every figure Seres Therapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.